# Innate Pharma Q2 Earnings Highlights

> Innate Pharma secures $75m Sobi deal for cancer drug.
- Title: Innate Pharma Q2 Earnings Highlights · Yahoo Finance
- Summary: Innate Pharma secures $75m Sobi deal for cancer drug. Innate Pharma's Q2 earnings call highlighted a $75 million upfront payment with Sobi for lacutamab…
- Keywords: innate pharma, sobi, lacutamab, q2 earnings, cancer drug, cash runway, phase iii trial, sezary syndrome, monalizumab, iph4502, antibody-drug conjugate, nasdaq ipha
- Source: Yahoo Finance — https://finance.yahoo.com/healthcare/articles/innate-pharma-q2-earnings-call-130224701.html
- Published: 2026-09-17T13:02:24+00:00
- Read time: 1 min
- Topics: innate pharma, sobi, lacutamab, q2 earnings, cancer drug, cash runway, phase iii trial, sezary syndrome, monalizumab, iph4502, antibody-drug conjugate, nasdaq ipha
## Sobi Partnership Details
Innate Pharma secured a $75 million upfront payment from Sobi for lacutamab, with additional €30 million equity financing.

> Innate Pharma strengthened its finances through a Sobi partnership for lacutamab, including a $75 million upfront payment, and a €30 million equity financing.
## Cash Runway Extension
The partnership and financing extend Innate's cash runway through the end of Q1 2028.

> The company expects its cash runway to extend through the end of Q1 2028.
## Lacutamab Phase III Trial
Lacutamab's TELLOMAK-3 phase III trial begins enrollment in Q1 2027 with potential accelerated approval for Sézary syndrome in H2 2027.

> Lacutamab's phase III TELLOMAK-3 trial has begun, with enrollment expected in Q1 2027 and a potential accelerated-approval filing for Sézary syndrome planned for the second half of 2027.
## Regulatory Designations
Lacutamab received FDA Breakthrough Therapy, Fast Track, EMA PRIME, and orphan-drug designations in the U.S. and Europe.

> Jensen said lacutamab has received FDA Breakthrough Therapy designation for relapsed or refractory Sézary syndrome, as well as FDA Fast Track designation, European Medicines Agency PRIME designation, and orphan-drug designations in the U.S. and Europe.
## Monalizumab Phase III Readout
PACIFIC-9 phase III trial for monalizumab enrolls 1,051 patients with unresectable stage III non-small cell lung cancer.

> Enrollment has been completed in PACIFIC-9, a randomized phase III trial of monalizumab in unresectable stage III non-small cell lung cancer.
## IPH4502 Clinical Data
IPH4502 shows preliminary responses in heavily pretreated solid tumors after prior enfortumab vedotin treatment.

> Innate reported preliminary antitumor activity, including objective responses in heavily pretreated patients with urothelial cancer after prior enfortumab vedotin treatment.
## Next Steps for IPH4502
Innate plans to present initial phase I dose-escalation data at EORTC-NCI-AACR meeting in Barcelona on November 18.

> Innate plans to present initial phase I dose-escalation data at the EORTC-NCI-AACR meeting in Barcelona in November.
## Financial Position
Innate has €21.4 million cash equivalents as of June 30, 2026, excluding €65 million Sobi payment and €30 million equity offering.

> Chief Financial Officer Frédéric Lombard said Innate had €21.4 million in cash equivalents and financial assets as of June 30, 2026.
## Key takeaway

Innate Pharma's Q2 earnings call highlighted a $75 million upfront payment with Sobi for lacutamab, extending cash runway to Q1 2028.